Demand for GLP1 receptor agonists is further accelerated by the growing global burden of type 2 diabetes
Jahan S, Abid A, Khalid S, Afsar T, Ain QU, Shaheen G, et al
Therapeutic strategies include induced lipid peroxidation, adjustment of iron homeostasis, increase of PUFA bioavailability and combination of ferroptosis promoting agents with conventional treatments
But more and more research suggests that #amylin agonists might be the next big thing in #obesity and diabetes treatment
Everyones timeline to suppress appetite is different depending on various factors like individuals metabolism and lifestyle, etc., so you should consult with a healthcare professional
Your insights could help others on their journey to better health